Saturday, 28 November, 2020

Oxford scientists expect COVID-19 vaccine data by Christmas

NHS 'to start COVID vaccination of all adults by end of January' Almost a million people have been given an experimental Chinese coronavirus vaccine, pharmaceutical giant claims
Ginger Lawrence | 22 November, 2020, 11:05

As China rushes to keep up with the global race to find a coronavirus vaccine, a state-owned drugmaker is reporting promising results for a candidate after administering doses to almost a million people in the country.

After getting permission to use the experimental vaccine in China, the pharmaceutical company Can Sino Biologics announced that it has also received special permission to apply the experimental vaccine to Chinese army personnel.

Based on these interim safety and efficacy data, Moderna intends to submit for an Emergency Use Authorisation (EUA) with the US Food and Drug Administration (USFDA) in the coming weeks and anticipates having the EUA informed by the final safety and efficacy data.

Compared with other Covid-19 vaccine candidates such as viral-vectored vaccines or DNA or RNA vaccines, according to the researchers, the occurrence of fever after vaccination with CoronaVac was relatively low.

It's unclear which vaccine Liu referred to, and Sinopharm was not immediately available to comment. This vaccine has been given to 1 million people, but has not shown any serious side effects. The vaccine uses a chimpanzee adenovirus which has been genetically modified to have the same external spike proteins as SARS-CoV-2, the virus behind Covid-19.

Apple to pay $113m to settle iPhone 'batterygate'
This new investigation was launched by more than 30 states, including Arizona , Arkansas, and IN , according to a press release. A judge is yet to approve the new settlement of up to US$ 113 million , so it may be a while before Apple compensates anyone.

"It is essential that a COVID-19 vaccine can be effective across a broad age range, particularly in older individuals where they are disproportionately at risk of severe COVID-19 disease". They have recruited approximately 60,000 people and blood samples of over 40,000 for their trials.

A coronavirus vaccine created by a collaboration between drugmaker AstraZeneca and the University of Oxford is showing results that it is safe and triggers a similar immune response among adults of all ages, according to preliminary results of their phase 2 study.

Since the announcement by the American company Pfizer to make 95 percent effective corona vaccine, many countries have claimed to make effective vaccine. However, no adverse reactions have been reported by the state, the company or the trial participants, said Sinopharm.

While doses of the vaccine candidates are forecast to be made before the end of 2020 the firms each said global rollouts are likely to take place next year.